Key result
Baseline beta-blocker use shows no 5-year mortality benefit in stable CAD.
Why the study?
The effect of first-line antianginal agents, β-blockers, and calcium antagonists on clinical outcomes in stable CAD remains uncertain.
Does the use of β-blockers or calcium antagonists reduce mortality in patients with stable coronary artery disease?
Cohort (n=22,006)
Yes
Does the use of β-blockers or calcium antagonists reduce mortality in patients with stable coronary artery disease?
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“systematic use of beta-blockers is not mandated for all patients with stable coronary artery disease, especially in the absence of previous myocardial infarction”
In patients with stable coronary artery disease, routine use of β-blockers or calcium antagonists is not associated with improved survival, except for β-blockers in the first year following a myocardial infarction.
AIMS: The effect of first-line antianginal agents, β-blockers, and calcium antagonists on clinical outcomes in stable coronary artery disease (CAD) remains uncertain. METHODS AND RESULTS: We analysed the use of β-blockers or calcium antagonists (baseline and annually) and outcomes in 22 006 stable CAD patients (enrolled 2009-2010) followed annually to 5 years, in the CLARIFY registry (45 countries). Primary outcome was all-cause death. Secondary outcomes were cardiovascular death and the composite of cardiovascular death/non-fatal myocardial infarction (MI). After multivariable adjustment, baseline β-blocker use was not associated with lower all-cause death [1345 (7.8%) in users vs. 407 (8.4%) in non-users; hazard ratio (HR) 0.94, 95% confidence interval (CI) 0.84-1.06; P = 0.30]; cardiovascular death [861 (5.0%) vs. 262 (5.4%); HR 0.91, 95% CI 0.79-1.05; P = 0.20]; or cardiovascular death/non-fatal MI [1272 (7.4%) vs. 340 (7.0%); HR 1.03, 95% CI 0.91-1.16; P = 0.66]. Sensitivity analyses according to β-blocker use over time and to prescribed dose produced similar results. Among prior MI patients, for those enrolled in the year following MI, baseline β-blocker use was associated with lower all-cause death [205 (7.0%) vs. 59 (10.3%); HR 0.68, 95% CI 0.50-0.91; P = 0.01]; cardiovascular death [132 (4.5%) vs. 49 (8.5%); HR 0.52, 95% CI 0.37-0.73; P = 0.0001]; and cardiovascular death/non-fatal MI [212 (7.2%) vs. 59 (10.3%); HR 0.69, 95% CI 0.52-0.93; P = 0.01]. Calcium antagonists were not associated with any difference in mortality. CONCLUSION: In this contemporary cohort of stable CAD, β-blocker use was associated with lower 5-year mortality only in patients enrolled in the year following MI. Use of calcium antagonists was not associated with superior mortality, regardless of history of MI.
No takes yet. Share an insight, caveat, or question.
Sorbets et al. (2018) conducted a cohort in Stable coronary artery disease (CAD) (n=22,006). β-blockers vs. Non-users was evaluated on All-cause mortality (HR 0.94, 95% CI 0.84-1.06, p=0.30). Baseline use of β-blockers in patients with stable coronary artery disease was not associated with lower all-cause mortality at 5 years compared to non-users.
Synapse has enriched 10 related papers. Consider them for comparative context: